Precision Oncology Decisions

From biopsy slides to outcome-linked tissue intelligence

Aquila Path transforms routine prostate pathology into multidimensional tissue intelligence designed to support clearer biological risk assessment and more informed physician-led decisions.

Routine pathology reveals cancer. Understanding the risk within it is more complex.

The biological patterns associated with disease behavior may extend beyond what conventional grading alone can consistently represent. Aquila Path links patterns within prostate tissue to longitudinal outcomes, helping clinicians interpret how the disease may behave.

Understanding
Tissue Behavior

Clinical Context,
Clearly Connected

From Signal to
Confident Decision

Our TruGrade Technology

01 One Score, Total Clarity

TruGrade™ is presented as a biological risk assessment powered by the Aquila Path Foundation Model.

02 Routine Pathology. Extraordinary Potential.

Routine H&E biopsy tissue forms the computational foundation for tissue intelligence.

03 Morphology Becomes Spatial Biology

Aquila Path’s AI analyses how tissue structures and biological features are organized and related, revealing patterns that may be difficult to assess consistently through visual interpretation alone.

04 From Tissue Architecture to Tissue Intelligence

Tissue architecture, spatial relationships, and clinical context converge into a richer representation that captures the complexity of each patient's disease.

05 Biological Risk, Made Interpretable.

Multidimensional evidence contributes to a single TruGrade™ Score designed to support clearer risk interpretation and physician-led decisions.

One unified score from tissue intelligence

Outcome-linked intelligence from routine H&E

TruGrade™ integrates tissue morphology, gland architecture, spatial organization, and clinical context into a single interpretable risk signal designed to support clearer prostate cancer decisions.

4.2 Single evidence-guided TruGrade™ risk score

95% Confidence generated from convergent tissue signals

H&E Built for routine pathology workflows without additional staining

Scientific Foundation

Foundation at Scale

Built from the world's largest clinically linked pathology datasets and informed by long-term clinical outcomes, Aquila Path is designed to identify meaningful patterns and outcomes that matter in clinical practice.

100,000+

Prostate H&E Images

Purpose-built foundation model development using routine prostate biopsy and pathology images.

10,000+

Linked Clinical Outcomes

Outcome-linked learning from longitudinal patient cohorts.

10+ Years

Pathology Innovation

Expertise spanning AI, digital pathology, and diagnostics excellence.

Routine H&E

No Additional Staining

Designed to work from standard pathology workflows without specialized assays.

Spatial Intelligence

Beyond Conventional Grading

Models tissue architecture and spatial relationships, not simply isolated image features.

Outcome-Driven

Clinically Relevant Endpoints

Optimized using long-term clinical outcomes rather than image classification alone.

From uncertainty to evidence-guided direction

Aquila Path helps care teams move from complex oncology signals to clearer risk understanding, stronger patient conversations, and more structured precision oncology decisions.

High-resolution prostate pathology tissue slide

The Status Quo

Complex Information. High-Stakes Interpretation.

Clinical decisions rely on multiple sources of evidence that can be difficult to interpret consistently.

Multiple diagnostic signals require careful interpretation
Clinical, pathological, and patient data often exist in separate contexts

Aquila Path digital pathology platform on a clinical workstation

The TruGrade™ Score

One interpretable score. Greater biological context.

TruGrade™ integrates multidimensional tissue and clinical signals into a biological risk assessment designed to complement conventional pathology.

Adds outcome-linked tissue intelligence
Supports clearer risk interpretation
Fits with physician-led clinical evaluation

Clinicians reviewing pathology information together

The Clinical Value

More Confidence in Every Conversation

A more complete view of biological risk can help clinicians explain uncertainty, structure patient conversations, and consider next steps with greater confidence.

Makes biological risk easier to explain and discuss
Supports more structured conversations around prognosis and care planning
Keeps physician judgment and patient context central

Built for the people who carry each decision forward

Aquila Path translates tissue and clinical evidence into interpretable biological risk insight, helping clinicians assess disease and helping patients engage more meaningfully in the decisions that follow.

Clinician reviewing digital pathology results

Greater biological context at the point of judgment

Aquila Path complements conventional pathology with an interpretable view of biological risk, strengthening prognosis discussions, patient communication, and physician-led care planning.

Understand the TruGrade™ Score

Bring clearer precision oncology decision support to your institution

Partner with Aquila Path

Request the Clinical Brief